ORG Partners LLC Reduces Stake in Edwards Lifesciences Co. (NYSE:EW)

ORG Partners LLC decreased its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 20.4% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 755 shares of the medical research company’s stock after selling 194 shares during the period. ORG Partners LLC’s holdings in Edwards Lifesciences were worth $58,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in EW. Seascape Capital Management raised its holdings in shares of Edwards Lifesciences by 0.6% in the 4th quarter. Seascape Capital Management now owns 27,766 shares of the medical research company’s stock valued at $2,117,000 after acquiring an additional 170 shares in the last quarter. NewEdge Wealth LLC raised its holdings in shares of Edwards Lifesciences by 17.1% in the 4th quarter. NewEdge Wealth LLC now owns 7,098 shares of the medical research company’s stock valued at $541,000 after acquiring an additional 1,039 shares in the last quarter. Birch Hill Investment Advisors LLC increased its position in shares of Edwards Lifesciences by 1.0% during the 4th quarter. Birch Hill Investment Advisors LLC now owns 393,858 shares of the medical research company’s stock valued at $30,032,000 after purchasing an additional 3,789 shares during the last quarter. Braun Bostich & Associates Inc. increased its position in shares of Edwards Lifesciences by 49.6% during the 4th quarter. Braun Bostich & Associates Inc. now owns 5,047 shares of the medical research company’s stock valued at $385,000 after purchasing an additional 1,674 shares during the last quarter. Finally, Valeo Financial Advisors LLC increased its position in shares of Edwards Lifesciences by 63.1% during the 4th quarter. Valeo Financial Advisors LLC now owns 5,111 shares of the medical research company’s stock valued at $390,000 after purchasing an additional 1,978 shares during the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Insider Transactions at Edwards Lifesciences

In other news, VP Jean-Luc M. Lemercier sold 14,400 shares of the company’s stock in a transaction dated Monday, April 8th. The shares were sold at an average price of $92.32, for a total value of $1,329,408.00. Following the sale, the vice president now directly owns 173,849 shares of the company’s stock, valued at approximately $16,049,739.68. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, Director Michael A. Mussallem sold 29,350 shares of the stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $86.67, for a total transaction of $2,543,764.50. Following the sale, the director now directly owns 4,486 shares of the company’s stock, valued at approximately $388,801.62. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Jean-Luc M. Lemercier sold 14,400 shares of the stock in a transaction dated Monday, April 8th. The shares were sold at an average price of $92.32, for a total transaction of $1,329,408.00. Following the sale, the vice president now directly owns 173,849 shares in the company, valued at $16,049,739.68. The disclosure for this sale can be found here. Insiders have sold 194,004 shares of company stock valued at $17,166,254 in the last three months. 1.29% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several equities analysts have recently commented on the company. Truist Financial increased their price objective on Edwards Lifesciences from $78.00 to $84.00 and gave the company a “buy” rating in a research report on Friday, December 22nd. Evercore ISI increased their price objective on Edwards Lifesciences from $86.00 to $92.00 and gave the company an “in-line” rating in a research report on Thursday, April 4th. Wells Fargo & Company upgraded Edwards Lifesciences from an “equal weight” rating to an “overweight” rating and set a $94.00 price objective on the stock in a research report on Friday, February 2nd. StockNews.com lowered Edwards Lifesciences from a “buy” rating to a “hold” rating in a research report on Wednesday, March 20th. Finally, Citigroup raised their price target on Edwards Lifesciences from $90.00 to $98.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 3rd. One analyst has rated the stock with a sell rating, seven have given a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $91.73.

Edwards Lifesciences Price Performance

Shares of EW stock opened at $89.20 on Tuesday. The firm has a market cap of $53.69 billion, a P/E ratio of 38.78, a P/E/G ratio of 4.47 and a beta of 1.05. Edwards Lifesciences Co. has a fifty-two week low of $60.57 and a fifty-two week high of $96.12. The business’s 50 day moving average price is $90.07 and its 200-day moving average price is $77.92. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.40 and a current ratio of 3.38.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Tuesday, February 6th. The medical research company reported $0.64 earnings per share for the quarter, meeting the consensus estimate of $0.64. Edwards Lifesciences had a return on equity of 23.56% and a net margin of 23.35%. The company had revenue of $1.53 billion for the quarter, compared to analyst estimates of $1.50 billion. During the same period in the previous year, the company posted $0.64 earnings per share. The firm’s revenue was up 13.3% on a year-over-year basis. On average, equities research analysts anticipate that Edwards Lifesciences Co. will post 2.76 earnings per share for the current year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.